<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="publisher-id">AEU</journal-id>
            <journal-title-group>
                <journal-title>publication title</journal-title>
                <abbrev-journal-title abbrev-type="publisher">Arch. Esp. Urol.</abbrev-journal-title>
                <abbrev-journal-title abbrev-type="pubmed">Archivos Españoles de Urología</abbrev-journal-title>
            </journal-title-group>
            <issn pub-type="ppub">0004-0614</issn>
            <issn pub-type="epub">1576-8260</issn>
            <publisher>
                <publisher-name>publisher name</publisher-name>
                <publisher-name>publisher name</publisher-name>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.56434/j.arch.esp.urol.20227504.44</article-id>
            <article-id pub-id-type="publisher-id">1653726538703-615674591</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Article</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Oncologic outcomes and predictive factors for progression in pT3a renal cell carcinoma</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name-alternatives>
                        <name name-style="western">
                            <surname>Culpan</surname>
                            <given-names>Meftun
                            </given-names>
                        </name>
                    </name-alternatives>
                    <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
                    <xref ref-type="fn"><sup>*</sup></xref>
                    <email>mculpan@gmail.com</email>
                </contrib>
                <contrib contrib-type="author">
                    <name-alternatives>
                        <name name-style="western">
                            <surname>Iplikci</surname>
                            <given-names>Ayberk
                            </given-names>
                        </name>
                    </name-alternatives>
                    <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
                </contrib>
                <contrib contrib-type="author">
                    <name-alternatives>
                        <name name-style="western">
                            <surname>Kazan</surname>
                            <given-names>Huseyin
                                Ozgur
                            </given-names>
                        </name>
                    </name-alternatives>
                    <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
                </contrib>
                <contrib contrib-type="author">
                    <name-alternatives>
                        <name name-style="western">
                            <surname>Atis</surname>
                            <given-names>Gokhan
                            </given-names>
                        </name>
                    </name-alternatives>
                    <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
                </contrib>
                <contrib contrib-type="author">
                    <name-alternatives>
                        <name name-style="western">
                            <surname>Yildirim</surname>
                            <given-names>Asif
                            </given-names>
                        </name>
                    </name-alternatives>
                    <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
                </contrib>
                <aff-alternatives id="aff1">
                    <aff>
                        <addr-line><sup>1</sup>Department of Urology, Istanbul Medeniyet University, Faculty of Medicine, Istanbul, Turkey</addr-line>
                    </aff>
                </aff-alternatives>
            </contrib-group>
            <author-notes>
                <corresp id="cor1"><sup>*</sup>Correspondence: <email>mculpan@gmail.com</email> (Meftun Culpan)</corresp>
            </author-notes>


            <pub-date pub-type="epub">
                <day>28</day>
                <month>5</month>
                <year>2022</year>
            </pub-date>
            <pub-date pub-type="collection">
                <month>5</month>
                <year>2022</year>
            </pub-date>


            <volume>75</volume>
            <issue>4</issue>
            <fpage>310</fpage>
            <lpage>317</lpage>
            <abstract>
                <p><bold>Objectives:</bold> We aimed to evaluate oncologic outcomes of pT3a renal cell carcinoma (RCC)
                    patients that treated with radical or partial nephrectomy and identify clinical
                    or pathological factors that predict local recurrence or metastasis.
                    <bold>Methods:</bold> In this single center, retrospective study, we evaluated
                    medical records of 856 patients who underwent radical or partial nephrectomy for
                    RCC. Patients who had pT3aN0M0 RCC in final pathology and at least 6 months of
                    follow-up included in the study. Patients&#x2019; demographic characteristics,
                    laboratory parameters, tumor characteristics and oncological outcomes were
                    recorded. Cancer specific and overall survivals were our primary outcomes.
                    Multivariate analysis was performed to identify factors affecting oncologic
                    outcomes.
                    <bold>Results:</bold> A total of 86 pT3aN0M0 RCC patients were included final
                    analysis of our study. During the mean 60.75 months follow up, 3 patients (3.5%)
                    had experienced local recurrence and 19 patients (22.1%) had experienced
                    metastasis. Total of 24 patients (27.9%) had died during the follow up. In this
                    population 10-year OS was 70.8%, 10-year PFS was 61.3% and 10-year CSS was 78.4
                    %. In multivariate analysis, chronic renal failure (CRF) was an independent worse
                    prognostic factor for overall survival (p=0.03). Besides this sarcomatoid
                    differentiation was an independent prognostic factor for PFS, CSS and OS
                    (p=<inline-formula id="m1"><mml:math id="w1" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001).
                    <bold>Conclusions:</bold> Our study investigated the predictive factors for worse
                    oncologic outcomes in pT3aN0M0 RCC patients. Although many factors have
                    predictive value in univariate analysis, only sarcomatoid differentiation have
                    independent predictive value for worse CSS, PFS and OS. Besides sarcomatoid
                    differentiation, CRF is an independent prognostic factor for poor OS.</p>
            </abstract><kwd-group kwd-group-type="author">
            <kwd>chronic renal failure</kwd>
            <kwd>pT3a</kwd>
            <kwd>renal cell carcinoma</kwd>
            <kwd>sarcomatoid differentiation</kwd>
        </kwd-group>
        </article-meta>
    </front>
    <body>
        <sec id="S1">
            <!-- The element tags
       is currently not supported for the main body.
           -->
            <title>Introduction</title>
            <p id="S1.p1">Renal cancers are common urological malignancies with estimated 73750 new cases
                and 14830 deaths in 2020 and accounts for 5% in men and 3% in women of all
                cancers in USA (1). Renal cancers are mostly seen at the localized stage due to
                the development and widespread usage of imaging methods in recent years and
                partial or radical nephrectomy is the optimal treatment methods of localized or
                locally invasive diseases (2). Despite the proper surgical removal of tumors
                approximately 20-25% patients recur (3). Because of that, patients must
                follow-up conveniently according to risk classifications. Today, the most
                acceptable and commonly used risk classification is 2017 TNM classification
                system (4).</p>
            <p id="S1.p2">According to the TNM classification, tumors that <inline-formula id="S1.p2.m1"><mml:math id="w2" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&#x2264;" display="inline"><mml:mi mathvariant="normal">&#x2264;</mml:mi></mml:math></inline-formula> 7cm defined as T1
                and <inline-formula id="S1.p2.m2"><mml:math id="w3" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&gt;" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 7cm defined as T2 if tumor is limited to the kidney. However, if there is
                a tumor extension into major veins or perinephric tissues but not into the
                adrenal gland and not beyond gerota fascia, these tumors classified as pT3 tumors
                independent of tumor size. pT3a disease describe tumors that extends into renal
                vein or muscle containing segmental branches or tumors that invades perirenal
                and/or renal sinus fat (4). However, this classification constitutes a
                heterogeneous group in pT3a tumors. Perirenal fat invasions (PFI), renal sinus
                fat invasions (SFI) or venous invasions (VI) are defined as pT3a disease, either
                individually or all together and supposed to be equal for the prognosis. However,
                these invasion sites may have different prognostic features and there are some
                controversial reports about their prognostic values (5). Besides invasion sites,
                multiple clinical or pathological factors such as age, comorbidities, type of
                surgery, tumor size, tumor histology, can affect the prognosis of pT3a RCC
                patients.</p>
            <p id="S1.p3">In this study, we aimed to evaluate oncologic outcomes of pT3a RCC patients that
                treated with radical or partial nephrectomy and identify clinical or pathological
                factors that predict local recurrence or metastasis.</p>
        </sec>
        <sec id="S2">
            <!-- The element tags
       is currently not supported for the main body.
           -->
            <title>Materials and Methods</title>
            <p id="S2.p1">After obtaining institutional ethical board approval, we reviewed medical
                records of patients who received nephrectomy (radical or partial) for initial
                treatment of RCC (n=856) between 2001 &#x2013; 2020 at our hospital. After evaluation
                of this patients&#x2019; pathological results, 141 patients were identified as pT3. All
                patients evaluated with computerized tomography (CT) or magnetic resonance
                imaging (MRI) for local tumor characteristics, clinical lymph node (LN) status or
                metastasis. After imaging methods, patients underwent radical or partial
                nephrectomy with open or laparoscopic technique. If there was enlarged regional
                LNs in imaging or existence of palpable LNs in operation, LN dissection was
                performed. After the surgical removal of the tumors, specimens were evaluated by
                an experienced uropathologists in our center. If renal tumor specimens contained
                any amount of sarcomatioid variant, we accepted that as sarcomatoid
                differentiation. All patients followed up 6 months interval until 3 year and then
                yearly. First 3 year, patients underwent imaging (with CT or MRI) yearly and then
                every 2 years routinely or in the presence of symptom suggestive of metastasis.
            </p>
            <p id="S2.p2">Only pT3a RCC patients included in our study. After reviewing the medical
                records, patients who were metastatic at the time of diagnosis, had lymph node
                involvement and had lacking in at least 6 months follow-up were excluded from the
                study. After the exclusion criteria total of 86 patients included in our study.
                We evaluated the patients&#x2019; demographics, pathologic and clinical tumor
                characteristics, and survival data. Demographics were patients&#x2019; age, body mass
                index (BMI), gender, comorbidities, smoking status, creatinine and estimated
                glomerular filtration rate (eGFR), complete blood count and Charlson Comorbidity
                Index (CCI). Pathologic and clinical tumor characteristics included laterality,
                type of surgery (open or laparoscopic, radical, or partial), clinical and
                pathological T stage and size, histological type, and Fuhrman grade, sarcomatoid
                differentiation, existence of PFI, SFI, VI, renal collecting system involvement
                or positive surgical margin. Lastly, local recurrence, metastasis, death, and
                time of this events were recorded. Tumor development in renal fossa or resection
                site were defined as local recurrence and tumor development in distant areas or
                retroperitoneal lymph nodes were defined as metastasis.</p>
            <p id="S2.p3">We evaluated the oncological outcomes such as progression free survival (PFS),
                cancer specific survival (CSS) and overall survival (OS) of pT3a RCC patients and
                factors affecting these oncologic outcomes. Statistical analysis was performed
                using SPSS Statistics ver. 22 software (SPSS, Chicago, IL, USA). Baseline
                characteristics of patients and tumors were defined using descriptive statistics.
                Kaplan-Meier survival analysis by log-rank test, was applied to show and compare
                the survivals between certain groups. While performing univariate analysis to
                determine the factors affecting survival, cox regression analysis was applied.
                Multivariate analysis was done by including factors that were statistically
                significant in univariate analysis. P-value <inline-formula id="S2.p3.m1"><mml:math id="w4" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula> 0.05 was considered as
                statistically significant.</p>
        </sec>
        <sec id="S3">
            <!-- The element tags
       is currently not supported for the main body.
           -->
            <title>Results</title>
            <p id="S3.p1">A total of 86 pT3aN0M0 RCC patients were included final analysis of our study
                with a mean 60.75 months follow up. Mean age of our patients was 57.4 <inline-formula id="S3.p1.m1"><mml:math id="w5" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm{}" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula>
                12.6 years and gender distribution were 62 men (72.1%) and 24 women (27.9%).
                Patients&#x2019; clinical characteristics and preoperative laboratory findings are
                summarized in Table <xref ref-type="table" rid="S3.T1">1</xref> and <xref ref-type="table" rid="S3.T2">2</xref>.</p>
            <table-wrap id="S3.T1"><label>Table 1.</label><caption><p><bold>Patients Characteristics</bold></p></caption><!-- The element tags
is currently not supported for the main body.
	-->
                <table>

                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;border-bottom:1px solid #000;">Age, years (Mean<inline-formula id="S3.T1.m1"><mml:math id="w6" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula>SD)</td>
                        <td style="border-top:1px solid #000;border-bottom:1px solid #000;">57,4 <inline-formula id="S3.T1.m2"><mml:math id="w7" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula> 12,6</td></tr>
                    <tr>
                        <td colspan="2">Sex, n (%)</td>
                        <td valign="top" align="center"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Male</td>
                        <td>62 (72.1)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Female</td>
                        <td>24(27.9)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">BMI, kg/m2 (Mean<inline-formula id="S3.T1.m3"><mml:math id="w8" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula>SD)</td>
                        <td style="border-top:1px solid #000;">27,6 <inline-formula id="S3.T1.m4"><mml:math id="w9" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula> 4,1</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Smoking status, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>No</td>
                        <td>31 (36.1)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Former smoker</td>
                        <td>42 (48.8)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Active smoker</td>
                        <td>13 (15.1)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Hypertension, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Yes</td>
                        <td>51 (59.3)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>No</td>
                        <td>35 (40.7)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Diabetes Mellitus, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Yes</td>
                        <td>20 (23.2)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>No</td>
                        <td>66 (76.8)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Coronary Heart Disease, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Yes</td>
                        <td>24 (27.9)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>No</td>
                        <td>62 (72.1)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Chronic Renal Failure, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Yes</td>
                        <td>18 (20.9)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>No</td>
                        <td>68 (79.1)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Stages of Chronic Renal Failure, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>G1: Normal (eGFR <inline-formula id="S3.T1.m5"><mml:math id="w10" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&gt;" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula>90 mL/min)</td>
                        <td>28 (32.6)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>G2: Mildly decreased (eGFR: 60-89 mL/min)</td>
                        <td>40 (46.5)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>G3a: Mildly - moderately deceased(eGFR: 45-59 mL/min)</td>
                        <td>13 (15.1)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>G3b: Moderately to severely decreased (eGFR: 30-44 mL/min)</td>
                        <td>3 (3.5)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>G4: Severely decreased (eGFR: 15-29 mL/min)</td>
                        <td>2 (2.3)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>G5: Kidney failure (eGFR<inline-formula id="S3.T1.m6"><mml:math id="w11" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula> 15 mL/min)</td>
                        <td>0 (0)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Charlson Comorbidity Index, median (Range)</td>
                        <td style="border-top:1px solid #000;">5 (2-12)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Side, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Left</td>
                        <td>44 (51.2)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Right</td>
                        <td>42 (48.8)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Surgical Approach, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Open</td>
                        <td>41 (47.7)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Laparoscopy</td>
                        <td>45 (52.3)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Nephrectomy Type, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Radical</td>
                        <td>75 (87.2)</td></tr>
                    <tr>
                        <td valign="top" align="center" style="border-bottom:1px solid #000;"></td>
                        <td style="border-bottom:1px solid #000;">Partial</td>
                        <td style="border-bottom:1px solid #000;">11 (12.8)</td></tr>

                </table></table-wrap>
            <table-wrap id="S3.T2"><label>Table 2.</label><caption><p><bold>Laboratory Parameters (Mean &#xB1; SD)</bold></p></caption><!-- The element tags
is currently not supported for the main body.
	-->
                <table>

                    <tr>
                        <td style="border-top:1px solid #000;">Preoperative Creatinine, mg/dl</td>
                        <td style="border-top:1px solid #000;">1.1</td>
                        <td style="border-top:1px solid #000;"><inline-formula id="S3.T2.m1"><mml:math id="w12" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td style="border-top:1px solid #000;">0.4</td></tr>
                    <tr>
                        <td>Preoperative eGFR, mL/min/1.73m<inline-formula id="S3.T2.m2"><mml:math id="w13" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="{}^{2}" display="inline"><mml:msup><mml:mi/><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula></td>
                        <td>82.4</td>
                        <td><inline-formula id="S3.T2.m3"><mml:math id="w14" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td>24.5</td></tr>
                    <tr>
                        <td>Postoperative 6. Month eGFR, mL/min/1.73m<inline-formula id="S3.T2.m4"><mml:math id="w15" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="{}^{2}" display="inline"><mml:msup><mml:mi/><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula></td>
                        <td>58.6</td>
                        <td><inline-formula id="S3.T2.m5"><mml:math id="w16" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td>21.1</td></tr>
                    <tr>
                        <td>Postoperative 12. Month eGFR, mL/min/1.73m<inline-formula id="S3.T2.m6"><mml:math id="w17" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="{}^{2}" display="inline"><mml:msup><mml:mi/><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula></td>
                        <td>59.2</td>
                        <td><inline-formula id="S3.T2.m7"><mml:math id="w18" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td>22.8</td></tr>
                    <tr>
                        <td>Last eGFR, mL/min/1.73m<inline-formula id="S3.T2.m8"><mml:math id="w19" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="{}^{2}" display="inline"><mml:msup><mml:mi/><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula></td>
                        <td>58.5</td>
                        <td><inline-formula id="S3.T2.m9"><mml:math id="w20" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td>23.5</td></tr>
                    <tr>
                        <td>Preoperative Hemoglobin, g/dl</td>
                        <td>13.1</td>
                        <td><inline-formula id="S3.T2.m10"><mml:math id="w21" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td>1.7</td></tr>
                    <tr>
                        <td>Preoperative Leukocyte</td>
                        <td>8285.2</td>
                        <td><inline-formula id="S3.T2.m11"><mml:math id="w22" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td>2512.0</td></tr>
                    <tr>
                        <td>Preoperative Platelet</td>
                        <td>262884.9</td>
                        <td><inline-formula id="S3.T2.m12"><mml:math id="w23" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td>86512.5</td></tr>
                    <tr>
                        <td>Preoperative Neutrophil</td>
                        <td>5377.4</td>
                        <td><inline-formula id="S3.T2.m13"><mml:math id="w24" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td>2191.4</td></tr>
                    <tr>
                        <td>Preoperative Lymphocyte</td>
                        <td>2077.8</td>
                        <td><inline-formula id="S3.T2.m14"><mml:math id="w25" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td>779.7</td></tr>
                    <tr>
                        <td>Neutrophil-lymphocyte ratio (NLR)</td>
                        <td>3.0</td>
                        <td><inline-formula id="S3.T2.m15"><mml:math id="w26" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td>1.9</td></tr>
                    <tr>
                        <td style="border-bottom:1px solid #000;">Platelet-lymphocyte ratio (PLR)</td>
                        <td style="border-bottom:1px solid #000;">149.8</td>
                        <td><inline-formula id="S3.T2.m16"><mml:math id="w27" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula></td>
                        <td style="border-bottom:1px solid #000;">100.0</td></tr>

                </table></table-wrap>
            <p id="S3.p2">Forty-eight patients (55.9%) were defined as cT3a preoperatively, however 38
                patients (44.1%) were upgraded to pT3a from lower clinical stages (3 patients
                cT1a, 15 patients cT1b, 13 patients cT2a and 7 patients cT2b). Forty-one patients
                (47.7%) had operated with open technique and 45 (52.3%) patients had operated
                with laparoscopic technique. Seventy-five patients (87.2%) had performed radical
                nephrectomy and 11 patients (12.8%) had performed partial nephrectomy. The mean
                pathological tumor size was 73.9 <inline-formula id="S3.p2.m1"><mml:math id="w28" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm{}" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula> 30.1mm and most of our patients (84.9%)
                had clear cell histology. Fifty-three patients (61.6%) have had PFI, 43 patients
                (50%) have had SFI and 37 patients (43%) have had VI. Six patients (7%) have
                had sarcomatoid differentiation in final pathological analysis. Detailed
                pathological characteristics of tumors summarized in Table <xref ref-type="table" rid="S3.T3">3</xref>.</p>
            <table-wrap id="S3.T3"><label>Table 3.</label><caption><p><bold>Tumor pathological characteristics</bold></p></caption><!-- The element tags
is currently not supported for the main body.
	-->
                <table>

                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">cT Stage, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>T1a</td>
                        <td>3 (3.5)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>T1b</td>
                        <td>15 (17.4)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>T2a</td>
                        <td>13 (15.1)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>T2b</td>
                        <td>7 (8.1)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>T3a</td>
                        <td>48 (55.9)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Pathological tumor size, mm (Mean <inline-formula id="S3.T3.m1"><mml:math id="w29" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula> SD)</td>
                        <td style="border-top:1px solid #000;">73.9<inline-formula id="S3.T3.m2"><mml:math id="w30" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="\pm" display="inline"><mml:mo>&#xB1;</mml:mo></mml:math></inline-formula>30.1</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Fuhrmann Grade, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Grade 1</td>
                        <td>3 (3.7)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Grade 2</td>
                        <td>47 (58)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Grade 3</td>
                        <td>22 (27.2)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Grade 4</td>
                        <td>9 (11.1)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>NA</td>
                        <td>5</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Histology, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Clear Cell</td>
                        <td>73 (84.9)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Papillary, Type 1</td>
                        <td>5 (5.8)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Papillary, Type 2</td>
                        <td>0 (0)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Chromophobe</td>
                        <td>8 (9.3)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Perirenal Fat Invasion, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>No</td>
                        <td>33 (38.4)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Yes</td>
                        <td>53 (61.6)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Renal Sinus Fat Invasion, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>No</td>
                        <td>43 (50)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Yes</td>
                        <td>43 (50)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Venous Invasion, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>No</td>
                        <td>49 (57)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Yes</td>
                        <td>37 (43)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Collecting System Involvement, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>No</td>
                        <td>79 (91.9)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Yes</td>
                        <td>7 (8.1)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Localization of invasion, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Only Perirenal fat invasion</td>
                        <td>22 (25.6)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Only Renal sinus invasion</td>
                        <td>14 (16.3)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Only Renal vene or segmental artery invasion</td>
                        <td>12 (14)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Perirenal fat + Renal sinus Invasion</td>
                        <td>13 (15.1)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Perirenal fat + Renal Vein Invasion</td>
                        <td>9 (10.5)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Renal sinus + Renal Vein Invasion</td>
                        <td>7 (8.1)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Perirenal fat + Renal sinus + Renal Vein Invasion</td>
                        <td>9 (10.5)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Sarcomatoid differentiation, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>No</td>
                        <td>80 (93)</td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Yes</td>
                        <td>6 (7)</td></tr>
                    <tr>
                        <td colspan="2" style="border-top:1px solid #000;">Surgical Margin, n (%)</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td valign="top" align="center" ></td>
                        <td>Negative</td>
                        <td>84 (97.7)</td></tr>
                    <tr>
                        <td valign="top" align="center" style="border-bottom:1px solid #000;"></td>
                        <td style="border-bottom:1px solid #000;">Positive</td>
                        <td style="border-bottom:1px solid #000;">2 (2.3)</td></tr>

                </table></table-wrap>
            <p id="S3.p3">During the mean 60.75 months follow up, 3 patients (3.5%) had experienced local
                recurrence and 19 patients (22.1%) had experienced metastasis. Total of 24
                patients (27.9%) had died during the follow up and 14 of these patients (16.2%)
                had died because of RCC and 10 patients (11.7%) had died from other reasons
                except from RCC. In pT3a RCC population, 10-year OS was 70.8%, 10-year PFS was
                61.3% and 10-year CSS was 78.4 % (Figure <xref ref-type="fig" rid="S3.F1">1</xref>).
            </p>
            <fig id="S3.F1"><label>Fig. 1.</label>
                <caption>
                    <p>Overall survival, progression free survival and cancer
                        specific survival probabilities for pT3aN0M0 RCC patients. <bold>A)</bold> The 5-,
                        10- and 15-year OS rates were 79.3%, 70.8% and 49.7%, respectively.
                        <bold>B)</bold> The 5-, 10- and 15-year PFS rates were 77.0%, 61.3% and 54.5%,
                        respectively. <bold>C)</bold> The 5-, 10- and 15-year CSS rates were 87.9%, 78.4%
                        and 55.0%, respectively.</p>
                </caption>
                <!-- The element tags
         is currently not supported for the main body.
             -->
                <alternatives>
                    <graphic specific-use="online" xlink:href="1576-8260-75-4-310/fig1.jpg" id="S3.F1.g1"/>
                </alternatives>
            </fig>
            <p id="S3.p4">Among all patients, univariate analysis showed that, severity of chronic renal
                failure (CRF) (p=0.002), preoperative creatinine (p<inline-formula id="S3.p4.m1"><mml:math id="w31" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001), preoperative, 6.
                months and last follow up eGFR (p<inline-formula id="S3.p4.m2"><mml:math id="w32" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001, p=0.04 and p<inline-formula id="S3.p4.m3"><mml:math id="w33" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001, respectively),
                preoperative neutrophil/lymphocyte ratio (NLR) (p=0.02), preoperative
                platelet/lymphocyte ratio (PLR) (p<inline-formula id="S3.p4.m4"><mml:math id="w34" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001), Fuhrmann grade (p=0.01) and
                sarcomatoid differentiation (p<inline-formula id="S3.p4.m5"><mml:math id="w35" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001) were significant predictors of poor OS.
                However, Multivariate Cox proportional hazards method demonstrated that only
                severity of CRF (p=0.03) and sarcomatoid differentiation (p<inline-formula id="S3.p4.m6"><mml:math id="w36" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001) were
                significant predictors of poor OS outcomes. Our analysis for CSS showed that in
                univariate analysis preoperative creatinine (p<inline-formula id="S3.p4.m7"><mml:math id="w37" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001), last follow up eGFR
                (p=0.03) and sarcomatoid differentiation (p<inline-formula id="S3.p4.m8"><mml:math id="w38" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001) were significant predictive
                factors for CSS. In multivariate analysis only sarcomatoid differentiation
                (p<inline-formula id="S3.p4.m9"><mml:math id="w39" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001) was significant predictor for poor CSS. Lastly, in univariate
                analysis Fuhrmann grade (p=0.01) and sarcomatoid differentiation (p<inline-formula id="S3.p4.m10"><mml:math id="w40" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001) were
                significant predictors for PFS, however in multivariate analysis only sarcomatoid
                differentiation (p<inline-formula id="S3.p4.m11"><mml:math id="w41" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001) was significant predictor for PFS (Table <xref ref-type="table" rid="S3.T4">4</xref>).
            </p>
            <table-wrap id="S3.T4"><label>Table 4.</label><caption><p><bold>Factors affecting Overall Survival, Cancer Specific Survival and Progression Free Survival</bold></p></caption><!-- The element tags
is currently not supported for the main body.
	-->
                <table>

                    <tr>
                        <td colspan="7" style="border-top:1px solid #000;">Overall Survival</td></tr>
                    <tr>
                        <td/>
                        <td colspan="3" style="border-top:1px solid #000;border-bottom:1px solid #000;">Univariate Analysis</td>
                        <td colspan="3" style="border-top:1px solid #000;border-bottom:1px solid #000;">Multivariate Analysis</td></tr>
                    <tr>
                        <td/>
                        <td >OR</td>
                        <td >95 CI %</td>
                        <td >p</td>
                        <td >OR</td>
                        <td >95 CI %</td>
                        <td>p</td></tr>
                    <tr>
                        <td style="border-top:1px solid #000;">Age</td>
                        <td style="border-top:1px solid #000;">1.03</td>
                        <td style="border-top:1px solid #000;">0.995-1.072</td>
                        <td style="border-top:1px solid #000;">0.09</td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td>
                        <td valign="top" align="center" style="border-top:1px solid #000;"></td></tr>
                    <tr>
                        <td>Chronic Renal Failure stage</td>
                        <td>2.09</td>
                        <td>1.301-3.386</td>
                        <td>0.002</td>
                        <td>1.95</td>
                        <td>1.038-3.644</td>
                        <td>0.03</td></tr>
                    <tr>
                        <td>Preoperative Creatinine</td>
                        <td>6.84</td>
                        <td>2.409-19.389</td>
                        <td><inline-formula id="S3.T4.m1"><mml:math id="w42" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>Preoperative eGFR</td>
                        <td>0.97</td>
                        <td>0.942-0.990</td>
                        <td><inline-formula id="S3.T4.m2"><mml:math id="w43" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>6.Month eGFR</td>
                        <td>0.96</td>
                        <td>0.927-0.999</td>
                        <td>0.04</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>Last eGFR</td>
                        <td>0.96</td>
                        <td>0.943-0.988</td>
                        <td><inline-formula id="S3.T4.m3"><mml:math id="w44" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>Preoperative Neutrophil/ Lymphocyte Ratio</td>
                        <td>1.24</td>
                        <td>1.024-1.516</td>
                        <td>0.02</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>Preoperative Platelet/ Lymphocyte Ratio</td>
                        <td>1.00</td>
                        <td>1.001-1.007</td>
                        <td><inline-formula id="S3.T4.m4"><mml:math id="w45" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>Histology</td>
                        <td>1.47</td>
                        <td>0.985-2.211</td>
                        <td>0.05</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>Fuhrman Grade</td>
                        <td>2.07</td>
                        <td>1.165-3.700</td>
                        <td>0.01</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>Sarcomatoid differentiation</td>
                        <td>9.15</td>
                        <td>3.105-26.974</td>
                        <td><inline-formula id="S3.T4.m5"><mml:math id="w46" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td>
                        <td>17.33</td>
                        <td>5.128-58.588</td>
                        <td><inline-formula id="S3.T4.m6"><mml:math id="w47" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td></tr>
                    <tr>
                        <td colspan="7" style="border-top:1px solid #000;">Cancer Specific Survival</td></tr>
                    <tr>
                        <td>Preoperative Creatinine</td>
                        <td>6.30</td>
                        <td>1.617-24.577</td>
                        <td><inline-formula id="S3.T4.m7"><mml:math id="w48" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>Last eGFR</td>
                        <td>0.97</td>
                        <td>0.945-0.998</td>
                        <td>0.03</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>Fuhrman Grade</td>
                        <td>1.98</td>
                        <td>0.998-3.993</td>
                        <td>0.05</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td>Sarcomatoid differentiation</td>
                        <td>11.81</td>
                        <td>3.310-42.098</td>
                        <td><inline-formula id="S3.T4.m8"><mml:math id="w49" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td>
                        <td>64.15</td>
                        <td>6.561-627.387</td>
                        <td><inline-formula id="S3.T4.m9"><mml:math id="w50" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td></tr>
                    <tr>
                        <td colspan="7" style="border-top:1px solid #000;">Progression Free Survival</td></tr>
                    <tr>
                        <td>Fuhrman Grade</td>
                        <td>2.08</td>
                        <td>1.186-3.662</td>
                        <td>0.01</td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td>
                        <td valign="top" align="center" ></td></tr>
                    <tr>
                        <td style="border-bottom:1px solid #000;">Sarcomatoid differentiation</td>
                        <td style="border-bottom:1px solid #000;">20.20</td>
                        <td style="border-bottom:1px solid #000;">5.743-71.063</td>
                        <td style="border-bottom:1px solid #000;"><inline-formula id="S3.T4.m10"><mml:math id="w51" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td>
                        <td style="border-bottom:1px solid #000;">19.42</td>
                        <td style="border-bottom:1px solid #000;">5.510-68.416</td>
                        <td style="border-bottom:1px solid #000;"><inline-formula id="S3.T4.m11"><mml:math id="w52" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&lt;" display="inline"><mml:mo>&lt;</mml:mo></mml:math></inline-formula>0.001</td></tr>

                </table></table-wrap>
        </sec>
        <sec id="S4">
            <!-- The element tags
       is currently not supported for the main body.
           -->
            <title>Discussion</title>
            <p id="S4.p1">In this study, we evaluated the oncologic outcomes of pT3aN0M0 RCC patients and
                predicting factors of poor oncologic outcomes. Our results showed that patients
                with sarcomatoid differentiation have the worst PFS, CSS and OS. Besides that,
                CRF had been a significant predictor of poor OS results. However other parameters
                that considered to be potential risk factors such as type of surgery (partial or
                radical) or invasion site (PFI, SFI or VI) had no impact on oncologic results.</p>
            <p id="S4.p2">Sarcomatoid differentiation in RCC is a rare entity that accounts for 1-8% of
                all RCC patients and several former studies demonstrated that RCC with
                sarcomatoid differentiation was associated with poor oncological outcome for all
                stage RCC patients (6). In our study, we evaluated multiple potential risk
                factors for poor oncologic outcome for pT3aN0M0 RCC patients, but sarcomatoid
                differentiation was the only poorly predictive factor for all survival outcomes
                &#x2013; PFS, CSS and OS - in multivariate analysis (Figure <xref ref-type="fig" rid="S4.F2">2</xref>). Six in 86 pT3aN0M0
                patients (7%) had sarcomatoid differentiation in our study. Several former
                studies found similar results like us. Hwang et all evaluated 1437 patients who
                underwent nephrectomy for RCC and reported that patients who had sarcomatoid
                differentiation have had poor CSS and OS (p=0.012 and p=0.002, respectively) in
                multivariate analysis (7). In another study, authors analyzed 1202 non-metastatic
                operated RCC patients and reported that sarcomatoid differentiation were
                significantly correlated with poor survival in univariate analysis, but this
                study was indicated that in multivariate analysis sarcomatoid differentiation was
                not an independent predictor of survival (8). Lastly, in recent systematic review
                and meta-analysis examining prognostic value and clinicopathological features of
                sarcomatoid differentiation in patients with RCC with 35 studies and 11261
                patients, was suggested that sarcomatoid differentiation is associated with poor
                clinical outcome and advanced clinicopathological features (9).</p>
            <fig id="S4.F2"><label>Fig. 2.</label>
                <caption>
                    <p>Kaplan-Meier analysis of overall survival, progression free
                        survival and cancer specific survival regarding sarcomatoid differentiation.</p>
                </caption>
                <!-- The element tags
         is currently not supported for the main body.
             -->
                <alternatives>
                    <graphic specific-use="online" xlink:href="1576-8260-75-4-310/fig2.jpg" id="S4.F2.g1"/>
                </alternatives>
            </fig>
            <p id="S4.p3">Several studies have evaluated the association of patients&#x2019; comorbidities with
                survival results of patients with RCC (10,11). Berger et al studied the impact of
                comorbidity on OS after nephrectomy for RCC and reported that comorbidity is an
                independent prognostic factor for OS (HR 1.37, 95% CI 1.16&#x2013;1.63, p=0.0002)
                (11). In our study we found that CCI was not a significant predictive factor for
                OS, but we have evaluated patients&#x2019; comorbidities separately and found that CRF
                was an independent prognostic factor for OS (p=0.03) (Figure <xref ref-type="fig" rid="S4.F3">3</xref>). It&#x2019;s known that
                chronic kidney disease (CKD) is associated with increased all cause and cardiovascular mortality. Besides
                this Weng et al. reported that CKD is a significant predictive of mortality in
                patients with liver, kidney and urinary tract cancer (12). Similarly to these
                findings, a study that examining prognostic effect of comorbid diseases on
                mortality in kidney cancer evaluated 5090 patients with kidney cancer and
                reported that CKD is a significant predictor of mortality (13).
            </p>
            <fig id="S4.F3"><label>Fig. 3.</label>
                <caption>
                    <p>Kaplan-Meier analysis of overall survival, progression free
                        survival and cancer specific survival regarding chronic renal failure stages.</p>
                </caption>
                <!-- The element tags
         is currently not supported for the main body.
             -->
                <alternatives>
                    <graphic specific-use="online" xlink:href="1576-8260-75-4-310/fig3.jpg" id="S4.F3.g1"/>
                </alternatives>
            </fig>
            <p id="S4.p4">As we mentioned previously, PFI, SFI and VI are defined as pT3a disease, either
                individually or all together and supposed to be equal for the prognosis according
                to TNM classification. Some recent studies claimed that this invasion sites have
                different prognostic value. In recent meta-analysis evaluated the difference in
                prognosis between SFI and PFI for pT3a RCC and revealed that SFI is associated
                with worse CSS than PFI (5). However contrary to this findings Guo S et al
                reported that PFI or SFI alone had equal CSS (p=0.286) results, but patients with
                PFI+SFI+VI had the worst CCS outcomes (p=0.011) (14). In another study, authors
                reviewed 266 pT3aN0M0 RCC patients after nephrectomy and found that VI was the
                only independent prognostic factor for CSS (15). As it can be seen there is no
                consensus about prognostic value of invasion sites of pT3aN0M0 RCC patients. In
                our study we found that PFI, SFI or VI had no significant predictive value for
                prognosis of pT3aN0M0 RCC. Similarly, to our findings, Margulis V et al.
                investigated 365 pT3a RCC patients with a mean 33.5 months follow up and reported
                that the location of extrarenal invasion was not a significant prognosticator of
                CSS (16). According to these findings we support that all current invasion sites
                (PFI, SFI or VI) should be classified as pT3a like current TNM classification.</p>
            <p id="S4.p5">In TNM classification, there is no size limit for pT3 RCC patients. Irrespective
                of the size if there is an extrarenal extension, tumors classified as T3 or T4.
                However, some studies have claimed that tumor size is a significant predictor of
                worse survival outcome for pT3a RCC. Some recent studies reported that pT3a
                tumors <inline-formula id="S4.p5.m1"><mml:math id="w53" xmlns:mml="http://www.w3.org/1998/Math/MathML" alttext="&gt;" display="inline"><mml:mo>&gt;</mml:mo></mml:math></inline-formula> 7 cm have poor survival outcomes such as recurrence free survival or
                CSS (17,18). In this study we found similar oncologic outcomes for different size
                tumors. Our findings conflict with studies suggesting that pT3a tumors must be
                reclassified according to tumor size and there are some studies support our
                results. In a study that evaluated the impact of tumor size on the predictive
                ability of the pT3a RCC, authors reported that PFI and SFI was significantly
                associated with mortality from RCC independent of tumor size (19).</p>
            <p id="S4.p6">Nuclear grade is a well-known prognosticator of worse clinical outcomes in RCC
                patients. Fuhrman et al. investigated 103 patients with RCC for the prognostic
                significance of morphologic parameters and reported that nuclear grade was
                significantly effective in predicting distant metastasis. In this study authors
                stated that there was no metastasis in 45 patients with stage 1 nuclear grade
                (20). More recently, Chen et al investigated the impact of Fuhrman grading in
                pT3a RCC patients and had reported that Fuhrman grade had an independent
                prognostic value for RFS (21). In our study, Fuhrman grade was a significant
                predictor of all oncologic outcomes (OS, RFS and CSS) in univariate analysis, but
                in multivariate analysis nuclear grading was not an independent predictor of any
                oncologic outcome in pT3a RCC patients.</p>
            <p id="S4.p7">In recent years some researchers have claimed that preoperative NLR or PLR could
                be used as predictive marker for poor oncologic outcomes (22,23). In our study we
                found that preoperative NLR and PLR were predictive markers for OS in univariate
                analysis but in multivariate analysis they were not a significant predictor of
                poor OS. Due to the conflicting findings, these results should be supported by
                studies with high level of evidence to be put into clinical use. Lastly, we found
                that there is no significant difference between different operation technique
                according to oncologic survivals. If the operation performed accordance with
                oncological principles, there is no significant difference between laparoscopic -
                open or radical &#x2013; partial nephrectomy according to oncologic outcomes (24&#x2013;27).</p>
            <p id="S4.p8">Retrospective nature of this study and lack of standardization of therapy and
                follow-ups is the main limitation of our study. This study is a single center
                study and although our center has been a reference center for RCC patients in
                recent years, the limited number of patients is one of the limitations that
                should be considered. Due to the limited number of patients, some possible
                prognostic factors such as Fuhrman grade may have been analyzed as statistically
                insignificant at multivariate analysis. Another limitation of this study was lack
                of pathological re-evaluation of the specimens. However, this study was conducted
                at tertiary referral center and most of the pathological evaluations were
                performed by the same 3 experienced uropathologists. Lastly, some potential
                predictive factor such as tumor necrosis or nephrometry scoring systems were not
                included our analysis. Although some limitations our study include homogenous
                patient population and have relatively longer follow up period than similar
                studies.</p>
        </sec>
        <sec id="S5">
            <!-- The element tags
       is currently not supported for the main body.
           -->
            <title>Conclusions</title>
            <p id="S5.p1">Our study investigated the predictive factors for worse oncologic outcomes in
                pT3aN0M0 RCC patients. Although many factors have predictive value in univariate
                analysis, only sarcomatoid differentiation have independent predictive value for
                worse CSS, PFS and OS. Besides sarcomatoid differentiation, CRF is an independent
                prognostic factor for poor OS.</p>
        </sec>
        <sec id="S6">
            <!-- The element tags
       is currently not supported for the main body.
           -->
            <title>Ethics Approval and Consent to Participate</title>
            <p id="S6.p1">All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p>
        </sec>
        <sec id="S7">
            <!-- The element tags
       is currently not supported for the main body.
           -->
            <title>Funding</title>
            <p id="S7.p1">This research received no external funding.
            </p>
        </sec>
        <sec id="S8">
            <!-- The element tags
       is currently not supported for the main body.
           -->
            <title>Conflict of Interest</title>
            <p id="S8.p1">The authors declare no conflict of interest.</p>
        </sec>
    </body>
    <back>
        <ack/>
        <glossary/>
        <ref-list>
            <title>References</title>
            <ref id="b1"><label>[1]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70(1):7&#x2013;30.
                </mixed-citation>
            </ref>
            <ref id="b2"><label>[2]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. European Urology. 2015;67(5):913&#x2013;24.
                </mixed-citation>
            </ref>
            <ref id="b3"><label>[3]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. European Urology Focus. 2019;5(5):857&#x2013;66.
                </mixed-citation>
            </ref>
            <ref id="b4"><label>[4]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th Edition. 8th ed. Brierley JD, Gospodarowicz MK, Wittekind C, editors. Wiley; 2017. 272.
                </mixed-citation>
            </ref>
            <ref id="b5"><label>[5]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Zhang Z, Yu C, Velet L, Li Y, Jiang L, Zhou F. The difference in prognosis between renal sinus fat and perinephric fat invasion for pT3a renal cell carcinoma: A meta-analysis. PLoS ONE. 2016;11(2):1&#x2013;11.
                </mixed-citation>
            </ref>
            <ref id="b6"><label>[6]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Wang Z, Zeng X, Chen R, Chen Z. Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma. Cancer Management and Research. 2018;10:5339&#x2013;47.
                </mixed-citation>
            </ref>
            <ref id="b7"><label>[7]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Jeon HG, Choi DK, Sung HH, Jeong BC, Seo S Il, Jeon SS, et al. Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival in Renal Cell Carcinoma Patients Undergoing Nephrectomy. Annals of Surgical Oncology. 2016;23(1):321&#x2013;7.
                </mixed-citation>
            </ref>
            <ref id="b8"><label>[8]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Shao Y, Xiong S, Sun G, Dou W, Hu X, Yang W, et al. Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma. Cancer Medicine. 2020;9(3):959&#x2013;70.
                </mixed-citation>
            </ref>
            <ref id="b9"><label>[9]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Zhang L, Wu B, Zha Z, Zhao H, Feng Y. The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: A systematic review and meta-analysis. Cancer Management and Research. 2018;10:1687&#x2013;703.
                </mixed-citation>
            </ref>
            <ref id="b10"><label>[10]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Ather MH, Nazim SM. Impact of Charlson&#x2019;s comorbidity index on overall survival following tumor nephrectomy for renal cell carcinoma. International Urology and Nephrology. 2010;42(2):299&#x2013;303.
                </mixed-citation>
            </ref>
            <ref id="b11"><label>[11]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Berger DA, Megwalu II, Vlahiotis A, Radwan MH, Serrano MF, Humphrey PA, et al. Impact of Comorbidity on Overall Survival in Patients Surgically Treated for Renal Cell Carcinoma. Urology. 2008;72(2):359&#x2013;63.
                </mixed-citation>
            </ref>
            <ref id="b12"><label>[12]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Weng PH, Hung KY, Huang HL, Chen JH, Sung PK, Huang KC. Cancer-specific mortality in chronic kidney disease: Longitudinal follow-up of a large cohort. Clinical Journal of the American Society of Nephrology. 2011;6(5):1121&#x2013;8.
                </mixed-citation>
            </ref>
            <ref id="b13"><label>[13]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Wong CS, Chen TT, Chang WP, Wong HSC, Wu MY, Adikusuma W, et al. Prognostic effect of comorbid disease and immune gene expression on mortality in kidney cancer&#x2014;a population based study. Cancers. 2020;12(6):1&#x2013;13.
                </mixed-citation>
            </ref>
            <ref id="b14"><label>[14]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Guo S, Liu Z, Li X, Yao K, Dong P, Chen D, et al. The prognostic value of the site of invasion in T3aN0M0 clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations. 2019;37(5):301.e11-301.e17.
                </mixed-citation>
            </ref>
            <ref id="b15"><label>[15]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Park M, Shim M, Kim M, Song C, Kim CS, Ahn H. Prognostic heterogeneity in T3aN0M0 renal cell carcinoma according to the site of invasion. Urologic Oncology: Seminars and Original Investigations. 2017;35(7):458.e17-458.e22.
                </mixed-citation>
            </ref>
            <ref id="b16"><label>[16]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Location of Extrarenal Tumor Extension Does Not Impact Survival of Patients With pT3a Renal Cell Carcinoma. Journal of Urology. 2007;178(5):1878&#x2013;82.
                </mixed-citation>
            </ref>
            <ref id="b17"><label>[17]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Chen L, Ma X, Li H, Gu L, Li X, Gao Y, et al. Influence of tumor size on oncological outcomes of pathological T3aN0M0 renal cell carcinoma treated by radical nephrectomy. PLoS ONE. 2017;12(3):2&#x2013;11.
                </mixed-citation>
            </ref>
            <ref id="b18"><label>[18]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Shimizu T, Miyake M, Hori S, Iida K, Ichikawa K, Sakamoto K, et al. Clinical significance of tumor size, pathological invasion sites including urinary collecting system and clinically detected renal vein thrombus as predictors for recurrence in pT3a localized renal cell carcinoma. Diagnostics. 2020;10(3).
                </mixed-citation>
            </ref>
            <ref id="b19"><label>[19]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Siddiqui SA, Frank I, Leibovich BC, Cheville JC, Lohse CM, Zincke H, et al. Impact of Tumor Size on the Predictive Ability of the pT3a Primary Tumor Classification for Renal Cell Carcinoma. Journal of Urology. 2007;177(1):59&#x2013;62.
                </mixed-citation>
            </ref>
            <ref id="b20"><label>[20]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. The American Journal of Surgical Pathology. 1982 Oct;6(7):655&#x2013;64.
                </mixed-citation>
            </ref>
            <ref id="b21"><label>[21]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Chen K, Lee BL, Huang HH, Tan BY, Lee LS, Ng LG, et al. Tumor size and Fuhrman grade further enhance the prognostic impact of perinephric fat invasion and renal vein extension in T3a staging of renal cell carcinoma. International Journal of Urology. 2017;24(1):51&#x2013;8.
                </mixed-citation>
            </ref>
            <ref id="b22"><label>[22]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Albisinni S, Pretot D, Al Hajj Obeid W, Aoun F, Quackels T, Peltier A, et al. The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes. Progres en Urologie. 2019;29(8&#x2013;9):423&#x2013;31.
                </mixed-citation>
            </ref>
            <ref id="b23"><label>[23]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Otunctemur A, Dursun M, Besiroglu H, Ozer K, Horsanali O, Ozbek E. Clinical significance of preoperative neutrophil - to - lymphocyte ratio in renal cell carcinoma. International Braz J Urol. 2016;42(4):678&#x2013;84.
                </mixed-citation>
            </ref>
            <ref id="b24"><label>[24]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Patel SH, Uzzo RG, Larcher A, Peyronnet B, Lane BR, Pruthi D, et al. Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical Genitourinary Cancer. 2020;1&#x2013;7.
                </mixed-citation>
            </ref>
            <ref id="b25"><label>[25]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Shvero A, Nativ O, Abu-Ghanem Y, Zilberman D, Zaher B, Levitt M, et al. Oncologic Outcomes of Partial Nephrectomy for Stage T3a Renal Cell Cancer. Clinical Genitourinary Cancer. 2018;16(3):e613&#x2013;7.
                </mixed-citation>
            </ref>
            <ref id="b26"><label>[26]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Peng D, He ZS, Li XS, Tang Q, Zhang L, Yang KW, et al. Partial nephrectomy for T3aN0M0 renal cell carcinoma: Shall we step forward? International Braz J Urol. 2017;43(5):849&#x2013;56.
                </mixed-citation>
            </ref>
            <ref id="b27"><label>[27]</label>
                <mixed-citation><!-- The element tag
is currently not supported for the back matter
	--><!-- The element tag with attributes
	role=autoref
is currently not supported for the back matter
	--> Bragayrac LAN, Abbotoy D, Attwood K, Darwiche F, Hoffmeyer J, Kauffman EC, et al. Outcomes of Minimal Invasive vs Open Radical Nephrectomy for the Treatment of Locally Advanced Renal-Cell Carcinoma. Journal of Endourology. 2016;30(8):871&#x2013;6.
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
</article>
